O. A. Kraevaya, E. A. Khakina, N. A. Emelianov, A. F. Shestakov, T. E. Sashenkova, D. V. Mishchenko, P. A. Troshin, “Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance”, Mendeleev Commun., 2024, Volume 34, Issue 2,Pages <nobr>178

This article is cited in 1 paper

Communications

Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance

O. A. Kraevaya^a, E. A. Khakina^b, N. A. Emelianov^a, A. F. Shestakov^ac, T. E. Sashenkova^a, D. V. Mishchenko^acd, P. A. Troshin^ae

^a Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Moscow Region, Russian Federation
^b A.N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences, Moscow, Russian Federation
^c Department of Fundamental Physical and Chemical Engineering, M.V. Lomonosov Moscow State University, Moscow, Russian Federation
^d Moscow Region State Pedagogical University, Mytishi, Moscow Region, Russian Federation
^e Zhengzhou Research Institute, Harbin Institute of Technology, Zhengzhou, China

Abstract: The supramolecular complexation of anthracycline antibiotic ruboxyl with water-soluble fullerene derivative was visualized by scattering scanning near-field optical microscopy, and the effects of this complexation on the antileukemic activity in vivo were evaluated. Treatment of mice with P388 lymphocytic leukemia with ruboxyl resulted in 13% of cured animals, while similar treatment with ruboxyl–fullerene derivative combination caused 63% curing.

Keywords: water-soluble fullerene derivative, ruboxyl, leukemia, vesicles, IR s-SNOM.

Language: English

DOI: 10.1016/j.mencom.2024.02.006

	*Supplementary materials:*
		Supplementary_data_1.pdf	748.4 Kb